CPT-012

**CPT-012** is an apparently preclinical, sponsor-coded **small molecule** drug candidate attributed in public drug-database sources to **Enabled Therapeutics**. Publicly accessible secondary sources describe it as a **P2Y12 receptor modulator** being explored for **Alzheimer's disease**, **inflammation**, and **inflammatory pain**, with overall development status listed as **preclinical**. However, I could not verify the asset in higher-confidence primary public sources such as ClinicalTrials.gov, a sponsor pipeline page naming CPT-012 directly, a patent clearly tied to this exact code, or a peer-reviewed paper naming the exact compound; accordingly, the program should be treated as **weakly validated in public sources** pending primary-source confirmation.